n(1)-methylnicotinamide has been researched along with Cancer of Head in 1 studies
N(1)-methylnicotinamide: RN given refers to parent cpd
1-methylnicotinamide : A pyridinium ion comprising nicotinamide having a methyl group at the 1-position. It is a metabolite of nicotinamide which was initially considered to be biologically inactive but has emerged as an anti-thrombotic and anti-inflammatory agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Full pharmacokinetic profiles of nicotinamide concentrations in plasma were analyzed repeatedly in 15 patients to determine the inter- and intra-patient variability in peak plasma concentrations and the optimum times for administering nicotinamide as a radiosensitizer." | 2.69 | Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. ( Bernier, J; Bieri, S; Bolla, M; Denekamp, J; Dennis, MF; Hagen, F; Kocagöncü, O; Rojas, A; Stratford, MR, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernier, J | 1 |
| Stratford, MR | 1 |
| Denekamp, J | 1 |
| Dennis, MF | 1 |
| Bieri, S | 1 |
| Hagen, F | 1 |
| Kocagöncü, O | 1 |
| Bolla, M | 1 |
| Rojas, A | 1 |
1 trial available for n(1)-methylnicotinamide and Cancer of Head
| Article | Year |
|---|---|
Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.
Topics: Administration, Oral; Area Under Curve; Carbon Dioxide; Carcinoma; Carcinoma, Non-Small-Cell Lung; C | 1998 |